New York, Oct. 18 – UBS AG, London Branch priced $125,000 of 0% trigger autocallable optimization securities due Oct. 23, 2019 linked to the American depositary shares of Teva Pharmaceutical Industries Ltd., according to a 424B2 filing with the Securities and Exchange Commission.
The notes will be called at par plus a call return of 23.05% per year if Teva Pharmaceutical shares close at or above the initial share price on any observation date, which occurs every quarter.
If the notes are not called and Teva Pharmaceutical shares finish at or above the trigger price, 70% of the initial share price, the payout at maturity will be par. Otherwise, investors will be exposed to the share price decline from the initial price.
UBS Financial Services Inc. and UBS Investment Bank are the underwriters.
| Issuer: | UBS AG, London Branch
|
| Issue: | Trigger autocallable optimization securities
|
| Underlying stock: | Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
|
| Amount: | $125,000
|
| Maturity: | Oct. 23, 2019
|
| Coupon: | 0%
|
| Price: | Par of $10.00
|
| Payout at maturity: | Par if Teva Pharmaceutical shares finish at or above trigger price; otherwise, full exposure to share price decline
|
| Call: | Automatically at par plus 23.05% per year if Teva Pharmaceutical shares close at or above initial share price on any observation date, which occurs every quarter
|
| Initial share price: | $14.62
|
| Trigger price: | $10.23, 70% of initial price
|
| Pricing date: | Oct. 18
|
| Settlement date: | Oct. 20
|
| Underwriters: | UBS Financial Services Inc. and UBS Investment Bank
|
| Fees: | 1.5%
|
| Cusip: | 90283D787
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
